Trial Profile
Effect of Certolizumab pegol on pregnancy outcomes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
- Focus Adverse reactions
- 05 Jun 2021 Results assessing pregnancy outcomes from the UCB Pharmacovigilance safety database, presented at the 22nd Annual Congress of the European League Against Rheumatism
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 09 May 2018 New trial record